What is Exicure, Inc.'s earnings per share (EPS)?

Exicure, Inc. (XCUR) reported diluted earnings per share of -$0.79 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Exicure, Inc. (XCUR) Financials

XCUR

FY2025 annual

Revenue $0 -100.0% YoY

Net Income -$4.9M +49.0% YoY

EPS (Diluted) -$0.79 YoY not available

Free Cash Flow -$8.6M -194.0% YoY

Market Cap $9.2M as of Sep 11, 2026

Price / Sales n/m revenue is not positive, FY2025

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 9.4x on $977K equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 11, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the XCUR SEC filings page.

Exicure, Inc. (XCUR) reported $0 in revenue for fiscal year 2025, down 100.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI XCUR FY2025 2026-08-29

External financing is substituting for internally generated cash as Exicure operates with a shrinking commercial base and minimal reinvestment.

Revenue contracted sharply from $28.8M in FY2022 to a fraction of that in FY2024, while the company still recorded a $12.2M operating loss. This combination indicates that operating costs have not reset to the business’s current commercial scale, rather than financing costs being the primary drag.

Cash conversion was less negative than the accounting result in FY2024: operating cash flow was -$2.91M versus net income of -$9.70M, suggesting noncash or working-capital effects softened the cash impact. A $13.4M financing inflow was several times the operating cash shortfall, while free cash flow matched operating cash flow because capital expenditures were negligible.

The balance sheet became less equity-buffered: liabilities stayed near $8.3M across FY2022 and FY2024, while equity fell to $6.77M. Debt-to-equity rose from 0.6x to 1.2x, indicating diminished capitalization cushion without a comparable increase in reported liabilities.

Financial Health Signals

Financial health score not available

Exicure, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-20.75

Exicure, Inc. scores -20.75, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($9.2M) relative to total liabilities ($10.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

1/7

Exicure, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Exicure, Inc. reported a net loss of $4.9M while operations used $8.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Exicure, Inc. reported an operating loss of $4.2M against $1K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

Exicure, Inc. generated $0 in revenue in Q2 2026.

EBITDA

-$1.0M

YoY+58.4%

QoQ+36.3%

Exicure, Inc.'s EBITDA was -$1.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 58.4% from the same quarter a year earlier. Against the prior quarter it is up 36.3%.

Net Income

-$1.1M

YoY+57.2%

QoQ+38.7%

Exicure, Inc. reported -$1.1M in net income in Q2 2026. This represents an increase of 57.2% from the same quarter a year earlier. Against the prior quarter it is up 38.7%.

EPS (Diluted)

-$0.18

YoY+56.1%

QoQ+37.9%

Exicure, Inc. earned -$0.18 per diluted share (EPS) in Q2 2026. This represents an increase of 56.1% from the same quarter a year earlier. Against the prior quarter it is up 37.9%.

Cash & Balance Sheet

Cash & Debt

$1.7M

YoY-78.1%

QoQ-34.1%

5Y CAGR-47.4%

Exicure, Inc. held $1.7M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

YoY+3.6%

QoQ+2.7%

5Y CAGR-40.5%

Exicure, Inc. had 7M shares outstanding in Q2 2026. This represents an increase of 3.6% from the same quarter a year earlier. Against the prior quarter it is up 2.7%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-114.7%

YoY-85.2pp

QoQ-27.6pp

Exicure, Inc.'s ROE was -114.7% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 85.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 27.6 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$174K

YoY-81.4%

QoQ-44.2%

Exicure, Inc. invested $174K in research and development in Q2 2026. This represents a decrease of 81.4% from the same quarter a year earlier. Against the prior quarter it is down 44.2%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

XCUR Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

XCUR quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Revenue	N/A	$0-100.0%	$500K	$0-100.0%	$28.8M	N/A	$16.6M+1181.9%	$1.3M+998.3%	$118K-98.8%	$9.7M+838.1%	$1.0M
R&D Expenses	N/A	$3.3M	$0-100.0%	$1.4M-92.8%	$19.8M-59.6%	$49.0M+52.6%	$32.1M+65.9%	$19.3M+37.0%	$14.1M+7.9%	$13.1M-4.2%	$13.7M
SG&A Expenses	N/A	$6.8M+25.4%	$5.4M-53.5%	$11.7M+7.6%	$10.9M-16.8%	$13.1M+31.5%	$10.0M+16.1%	$8.6M+9.7%	$7.8M+11.0%	$7.0M+99.1%	$3.5M
Operating Income	N/A	-$4.2M+65.4%	-$12.2M+18.4%	-$15.0M-719.0%	-$1.8M+97.1%	-$62.5M-145.9%	-$25.4M+4.4%	-$26.6M-22.0%	-$21.8M-109.7%	-$10.4M+35.6%	-$16.2M
EBITDA	N/A	-$4.0M+67.3%	-$12.2M+15.0%	-$14.4M-2050.0%	-$668K+98.9%	-$61.4M-149.0%	-$24.7M+5.9%	-$26.2M-22.2%	-$21.5M-110.9%	-$10.2M+36.3%	-$16.0M
Interest Expense	N/A	$1K-94.4%	$18K	$0-100.0%	$595K-64.8%	$1.7M+195.1%	$573K-27.1%	$786K+17.0%	$672K-15.5%	$795K+9.8%	$724K
Income Tax	N/A	-$634K-8025.0%	$8K	$0-100.0%	$209K	$0	$0	$0	$0	$0	$0
Net Income	N/A	-$4.9M+49.0%	-$9.7M+42.6%	-$16.9M-555.1%	-$2.6M+96.0%	-$64.1M-159.9%	-$24.7M+6.2%	-$26.3M-17.4%	-$22.4M-103.6%	-$11.0M+35.0%	-$16.9M
EPS (Basic)	N/A	-$0.79+83.4%	-$4.75+55.0%	-$10.55-1783.9%	-$0.56+97.4%	-$21.70-7650.0%	-$0.28	N/A	N/A	N/A	N/A
EPS (Diluted)	-$1.32	-$0.79	-$4.75	-$10.55	-$0.56	-$21.70	-$0.28	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	6M	2M	2M	5M	3M	87M	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$0	$0	N/A	$0	$0	$0-100.0%	N/A	$0
R&D Expenses	$174K-81.4%	$312K-61.4%	N/A	$888K	$935K	$808K	N/A	$0
SG&A Expenses	$889K-41.3%	$1.3M-41.8%	N/A	$1.5M+4.5%	$1.5M+22.6%	$2.2M+65.9%	N/A	$1.4M-40.2%
Operating Income	-$1.1M+58.0%	-$1.6M-156.1%	N/A	-$2.4M+7.0%	-$2.5M-103.2%	$2.9M+449.6%	N/A	-$2.6M+22.5%
EBITDA	-$1.0M+58.4%	-$1.6M-153.3%	N/A	-$2.3M+10.0%	-$2.4M-98.5%	$3.0M+460.0%	N/A	-$2.6M+19.1%
Interest Expense	N/A	N/A	N/A	$0-100.0%	N/A	N/A	N/A	$12K
Income Tax	$0	$0	N/A	$0-100.0%	$0	$0	N/A	$8K
Net Income	-$1.1M+57.2%	-$1.8M-160.7%	N/A	-$2.4M-123.4%	-$2.6M-336.8%	$3.0M+463.1%	N/A	-$1.1M+79.2%
EPS (Basic)	-$0.18+56.1%	-$0.29-159.2%	-$0.46+86.4%	-$0.39+31.6%	-$0.41-17.1%	$0.49+202.1%	-$3.39-2507.7%	-$0.57+81.3%
EPS (Diluted)	-$0.18+56.1%	-$0.29-159.2%	-$0.46+86.4%	-$0.39	-$0.41	$0.49	-$3.39	-$0.57
Diluted Shares (Avg)	6M+0.9%	6M+3.1%	N/A	6M	6M	6M	N/A	2M

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

XCUR Balance Sheet

XCUR quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Total Assets	$14.0M-6.7%	$15.1M+30.0%	$11.6M-50.4%	$23.3M-64.0%	$64.9M-35.4%	$100.4M-12.9%	$115.3M+300.8%	$28.8M-0.8%	$29.0M+40.9%	$20.6M
Current Assets	$4.6M-66.2%	$13.7M+575.5%	$2.0M-79.9%	$10.1M-77.0%	$43.7M-49.4%	$86.3M-23.5%	$112.8M+307.7%	$27.7M+0.1%	$27.6M+37.9%	$20.0M
Cash & Equivalents	$3.7M-70.1%	$12.5M+1432.8%	$816K-90.5%	$8.6M-75.2%	$34.6M+4.2%	$33.3M-31.4%	$48.5M+84.5%	$26.3M+2.0%	$25.8M+31.3%	$19.6M
Short-Term Investments	$0	$0	$0	$0-100.0%	$4.5M-90.8%	$48.8M-21.7%	$62.3M	$0	$0	$0
Accounts Receivable	N/A	N/A	N/A	N/A	$0-100.0%	$11K-31.3%	$16K	$0	$0	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$4.4M	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$10.1M+22.1%	$8.3M-3.1%	$8.5M+1.7%	$8.4M-84.3%	$53.6M+37.7%	$38.9M+12.8%	$34.5M+342.3%	$7.8M-13.4%	$9.0M-50.3%	$18.1M
Current Liabilities	$3.9M+26.6%	$3.1M+22.4%	$2.5M+53.1%	$1.6M-95.2%	$34.1M+148.0%	$13.7M-55.8%	$31.1M+1421.6%	$2.0M-39.1%	$3.4M-72.4%	$12.2M
Non-Current Liabilities	$6.2M+19.5%	$5.2M-13.7%	$6.0M-10.8%	$6.8M-65.4%	$19.6M-22.4%	$25.2M+635.0%	$3.4M-40.5%	$5.8M+1.9%	$5.7M-5.3%	$6.0M
Long-Term Debt	N/A	N/A	N/A	N/A	$0-100.0%	$16.6M	$0-100.0%	$4.9M+1.4%	$4.9M+9.0%	$4.5M
Total Equity	$3.9M-42.0%	$6.8M+123.4%	$3.0M-79.7%	$14.9M+32.9%	$11.2M-81.7%	$61.5M-23.8%	$80.7M+285.4%	$21.0M+4.9%	$20.0M+716.0%	$2.4M
Retained Earnings	-$204.2M-2.5%	-$199.3M-5.1%	-$189.6M-9.8%	-$172.6M-1.5%	-$170.1M-60.5%	-$106.0M-30.3%	-$81.3M-47.8%	-$55.0M-63.6%	-$33.6M-48.7%	-$22.6M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$11.4M-39.2%	$12.8M-38.3%	$14.0M-6.7%	$15.3M+43.6%	$18.7M+75.3%	$20.7M+93.1%	$15.1M+30.0%	$10.6M-17.9%
Current Assets	$2.3M-73.1%	$3.5M-68.8%	$4.6M-66.2%	$5.4M+109.2%	$8.6M+315.9%	$11.3M+672.7%	$13.7M+575.5%	$2.6M-15.9%
Cash & Equivalents	$1.7M-78.1%	$2.6M-75.0%	$3.7M-70.1%	$4.4M+1193.9%	$7.9M+1388.3%	$10.4M+2747.0%	$12.5M+1432.8%	$343K-62.8%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$4.4M+31.7%	$4.4M+31.7%	$4.4M	$3.3M	$3.3M	$3.3M	$0	N/A
Total Liabilities	$10.4M+5.5%	$10.7M+14.6%	$10.1M+22.1%	$8.3M-8.2%	$9.9M+8.8%	$9.3M+9.3%	$8.3M-3.1%	$9.1M+7.5%
Current Liabilities	$4.2M-8.7%	$4.5M+14.7%	$3.9M+26.6%	$2.8M-24.2%	$4.6M+33.2%	$3.9M+46.1%	$3.1M+22.4%	$3.7M+64.6%
Non-Current Liabilities	$6.3M+17.8%	$6.2M+14.6%	$6.2M+19.5%	$5.6M+2.6%	$5.3M-6.0%	$5.4M-7.4%	$5.2M-13.7%	$5.4M-12.8%
Total Equity	$977K-89.0%	$2.1M-81.6%	$3.9M-42.0%	$6.9M+348.3%	$8.9M+449.5%	$11.4M+415.7%	$6.8M+123.4%	$1.5M-65.7%
Retained Earnings	-$207.2M-4.2%	-$206.0M-5.0%	-$204.2M-2.5%	-$201.3M-4.8%	-$198.9M-4.1%	-$196.3M-3.1%	-$199.3M-5.1%	-$192.1M-2.1%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Long-Term Debt.

XCUR Cash Flow Statement

XCUR quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Operating Cash Flow	-$6.7M	-$8.6M-194.0%	-$2.9M+71.9%	-$10.4M+71.0%	-$35.7M-2.4%	-$34.8M+11.3%	-$39.3M-3081.8%	$1.3M+106.8%	-$19.5M+1.5%	-$19.8M-291.9%	-$5.0M
Depreciation & Amortization	N/A	$242K+764.3%	$28K-95.6%	$634K-45.5%	$1.2M+3.6%	$1.1M+46.6%	$766K+95.4%	$392K+9.5%	$358K+54.3%	$232K+28.9%	$180K
Stock-Based Compensation	N/A	$2K-90.9%	$22K-98.4%	$1.3M-1.5%	$1.4M-53.4%	$2.9M+34.6%	$2.2M+18.7%	$1.8M+1.7%	$1.8M+23.7%	$1.5M+114.4%	$682K
Capital Expenditures	N/A	$1K	$0	$0-100.0%	$10K-99.0%	$968K-69.5%	$3.2M+193.1%	$1.1M+1051.1%	$94K-89.8%	$926K+135.0%	$394K
Free Cash Flow	N/A	-$8.6M-194.0%	-$2.9M+71.9%	-$10.4M+71.0%	-$35.7M+0.3%	-$35.8M+15.7%	-$42.4M-18160.0%	$235K+101.2%	-$19.6M+5.5%	-$20.7M-280.5%	-$5.4M
Investing Cash Flow	$563K	-$1.8M	$0+100.0%	-$1.1M-123.0%	$4.7M-89.1%	$43.1M+324.8%	$10.1M+116.0%	-$63.4M-67380.9%	-$94K+89.8%	-$926K-135.0%	-$394K
Financing Cash Flow	$0	$1.6M-88.1%	$13.4M+264.8%	$3.7M+218.3%	-$3.1M-378.2%	$1.1M-92.6%	$15.1M-82.1%	$84.3M+319.8%	$20.1M-25.2%	$26.9M+323.9%	$6.3M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$887K+61.1%	-$1.1M+28.5%	-$1.1M-35.7%	-$3.5M-685.7%	-$2.3M-95.7%	-$1.6M-255.1%	-$845K-3.6%	-$449K+68.2%
Depreciation & Amortization	$40K-43.7%	$49K-19.7%	$28K+300.0%	$82K+1071.4%	$71K+914.3%	$61K+771.4%	$7K0.0%	$7K-95.3%
Stock-Based Compensation	N/A	N/A	N/A	N/A	N/A	$0-100.0%	N/A	$5K-90.0%
Capital Expenditures	N/A	N/A	-$213K	-$106K	N/A	N/A	$0	$0
Free Cash Flow	N/A	N/A	-$1.4M-60.9%	-$3.6M-709.4%	N/A	N/A	-$845K-3.6%	-$449K+68.2%
Investing Cash Flow	$0+100.0%	$0+100.0%	$455K	$108K	-$280K	-$2.1M	$0-100.0%	$0
Financing Cash Flow	$0	$0-100.0%	$0-100.0%	$0	$0-100.0%	$1.6M	$12.4M+1240300.0%	$0+100.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

XCUR Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

XCUR quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Operating Margin	N/A	-2446.4%	N/A	-6.3%	N/A	-153.1%	-2053.8%	-18490.7%	-107.1%	-1560.0%
Net Margin	N/A	-1940.2%	N/A	-9.0%	N/A	-148.5%	-2029.5%	-18994.1%	-113.3%	-1635.2%
Return on Equity	-126.0%+17.3pp	-143.3%+414.8pp	-558.0%-540.7pp	-17.3%+553.4pp	-570.7%-530.6pp	-40.1%-7.5pp	-32.6%+74.4pp	-107.0%-51.9pp	-55.1%+636.9pp	-692.0%
Return on Assets	-35.2%+29.2pp	-64.4%+81.6pp	-146.1%-135.0pp	-11.1%+87.8pp	-98.8%-74.3pp	-24.6%-1.7pp	-22.8%+55.1pp	-77.9%-39.9pp	-38.0%+44.3pp	-82.3%
Current Ratio	1.19-3.3x	4.45+3.6x	0.81-5.3x	6.13+4.9x	1.28-5.0x	6.29+2.7x	3.63-9.9x	13.54+5.3x	8.24+6.6x	1.65
Debt-to-Equity	2.58+1.4x	1.22-1.6x	2.82+2.3x	0.56+0.6x	0.00-0.3x	0.27+0.3x	0.00-0.2x	0.240.0x	0.24-1.6x	1.82
Asset Turnover	0.000.0x	0.030.0x	0.00-1.2x	1.24+1.2x	-0.01-0.2x	0.17+0.2x	0.010.0x	0.00-0.3x	0.34+0.3x	0.05
FCF Margin	N/A	-582.0%	N/A	-123.7%	N/A	-255.5%	18.1%	-16594.1%	-213.1%	-525.5%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-114.7%-85.2pp	-87.1%-113.6pp	N/A	-35.2%+35.4pp	-29.6%+7.6pp	26.5%+64.0pp	N/A	-70.6%+46.2pp
Return on Assets	-9.8%+4.1pp	-14.3%-28.9pp	N/A	-16.0%-5.7pp	-14.0%-8.4pp	14.6%+22.3pp	N/A	-10.3%+30.3pp
Current Ratio	0.56-1.3x	0.79-2.1x	1.19-3.3x	1.96+1.3x	1.89+1.3x	2.91+2.4x	4.45+3.6x	0.71-0.7x
Debt-to-Equity	10.67+9.6x	5.08+4.3x	2.58+1.4x	1.20-4.7x	1.11-4.5x	0.82-3.0x	1.22-1.6x	5.88+4.0x
Asset Turnover	0.000.0x	0.000.0x	N/A	0.000.0x	0.000.0x	0.000.0x	N/A	0.000.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Exicure, Inc. XCUR	FY2025	$0	-$4.9M	N/A	$9.2M	—
Q32 BIO INC QTTB	FY2025	$53.7M	$29.8M	55.5%	$319.1M	67/100
Lixte Biotechnology Hldgs Inc LIXT	FY2025	N/A	-$6.1M	N/A	$125.4M	—
Neuraxis Inc NRXS	FY2025	$3.6M	-$7.8M	N/A	$71.5M	43/100
Fibrobiologics FBLG	FY2025	N/A	-$18.6M	N/A	$11.5M	—
CytoMed Therapeutics Ltd GDTC	FY2025	$252K	-$3.1M	N/A	$9.6M	—

Where Exicure, Inc. Ranks

Frequently Asked Questions

What is Exicure, Inc.'s annual revenue?

Exicure, Inc. (XCUR) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Exicure, Inc.'s revenue growing?

Exicure, Inc. (XCUR) revenue declined by 100.0% year-over-year, from $500K to $0 in fiscal year 2025.

Is Exicure, Inc. profitable?

No, Exicure, Inc. (XCUR) reported a net income of -$4.9M in fiscal year 2025.

What is Exicure, Inc.'s EBITDA?

Exicure, Inc. (XCUR) had EBITDA of -$4.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Exicure, Inc.'s return on equity (ROE)?

Exicure, Inc. (XCUR) has a return on equity of -126.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Exicure, Inc.'s free cash flow?

Exicure, Inc. (XCUR) recorded an outflow of $8.6M in free cash flow during fiscal year 2025. This represents a -194.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Exicure, Inc.'s operating cash flow?

Exicure, Inc. (XCUR) recorded an outflow of $8.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Exicure, Inc.'s total assets?

Exicure, Inc. (XCUR) had $14.0M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Exicure, Inc.'s capital expenditures?

Exicure, Inc. (XCUR) invested $1K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Exicure, Inc. spend on research and development?

Exicure, Inc. (XCUR) invested $3.3M in research and development during fiscal year 2025.

How many shares does Exicure, Inc. have outstanding?

Exicure, Inc. (XCUR) had 6M shares outstanding as of fiscal year 2025.

What is Exicure, Inc.'s current ratio?

Exicure, Inc. (XCUR) had a current ratio of 1.19 as of fiscal year 2025, which is considered adequate.

What is Exicure, Inc.'s debt-to-equity ratio?

Exicure, Inc. (XCUR) had a debt-to-equity ratio of 2.58 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Exicure, Inc.'s return on assets (ROA)?

Exicure, Inc. (XCUR) had a return on assets of -35.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Exicure, Inc.'s P/E ratio?

Exicure, Inc. (XCUR) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $9.2M as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Exicure, Inc.'s price-to-sales ratio?

Exicure, Inc. (XCUR) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $9.2M as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Exicure, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Exicure, Inc. (XCUR) held $3.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $8.6M over that year. Dividing the one by the other, the reported balance equals about 5 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Exicure, Inc.'s Altman Z-Score?

Exicure, Inc. (XCUR) has an Altman Z-Score of -20.75, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Exicure, Inc.'s Piotroski F-Score?

Exicure, Inc. (XCUR) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Exicure, Inc.'s earnings high quality?

Exicure, Inc. (XCUR) reported a net loss of $4.9M while operations used $8.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Exicure, Inc. cover its interest payments?

Exicure, Inc. (XCUR) reported an operating loss of $4.2M against $1K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.